POLYCYTHEMIA VERA
Clinical trials for POLYCYTHEMIA VERA explained in plain language.
Never miss a new study
Get alerted when new POLYCYTHEMIA VERA trials appear
Sign up with your email to follow new studies for POLYCYTHEMIA VERA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo for rare blood cancer shows promise but trial halted early
Disease control TerminatedThis early-phase trial tested a combination of two drugs—ruxolitinib and CPX-351—in 12 people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The goal was to find the best dose and see if the combo could shrink cancer. However, the study was stop…
Matched conditions: POLYCYTHEMIA VERA
Phase: PHASE1, PHASE2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for blood cancer patients: drug shows promise in controlling disease
Disease control TerminatedThis study tested a drug called ruxolitinib in 73 people with two types of blood cancer—polycythemia vera or essential thrombocythemia—that were not helped by standard treatment. The goal was to see if the drug could safely reduce high blood cell counts and symptoms like an enlar…
Matched conditions: POLYCYTHEMIA VERA
Phase: PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Study aims to predict drug failure in rare blood cancer
Knowledge-focused TerminatedThis study looked at whether two simple blood test results—hemoglobin and red blood cell distribution width—could predict if a person with polycythemia vera would stop responding to the drug hydroxyurea. Researchers planned to follow 76 adults starting hydroxyurea for the first t…
Matched conditions: POLYCYTHEMIA VERA
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC